Should you hold shares of Strides Pharma Science Ltd.? Should you add shares of Bank of India at the current market price? Have you lost the chance to buy shares of ICICI Prudential Life Insurance Co. at an attractive price? Is it the right time to exit Saregama India Ltd.?
Prashanth Tapse, senior vice president (research) at Mehta Equities and Kunal Kamble, senior technical and derivatives analyst at Bonanza Porfolio provided insights on these investor queries and more on NDTV Profit’s Ask Profit show.
Strides Pharma Science (CMP: Rs 883.55)
Prashanth: Buy
-
The analyst remains positive about the pharmaceutical sector, expecting positive outcomes from the India–US agreement.
-
Leading pharmaceutical companies with significant exposure to the US market are expected to be the primary beneficiaries.
-
Although Strides Pharma has limited presence in the US, its current valuation makes it an appealing investment opportunity.
Bank of India (CMP: Rs 118.35)
Kunal: Hold
-
Maintain the position as long as the stock holds above Rs 110.
-
The analyst maintains a bullish outlook on public sector banks.
-
The stock is trading above key exponential moving averages, with healthy volume indicators supporting the upward trend.
ICICI Prudential Life Insurance (CMP: Rs 640.20)
Kunal: Hold
-
A double top pattern has emerged, showing potential bearish reversal.
-
A breakout below Rs 620 suggests early signs of downward movement.
-
However, the presence of higher highs and higher lows also points to possible bullish continuation.
-
Given the mixed signals, it’s advisable to hold the stock with a stop-loss at Rs 620 to manage risk effectively.
Saregama India (CMP: 496.35)
Kunal: Weak bullish trend
-
The stock has been consolidating within a range since September 2024.
-
There’s a possibility of further downside, potentially slipping to Rs 440 levels.
-
Declining volumes suggest weakening bullish sentiment and limited upward momentum.
Gulf Oil Lubricants India (CMP: Rs 1,266.50)
Prashanth: Positive for long term
-
From a long-term perspective, the stock is worth accumulating but not at the current price.
-
It’s best to adopt a wait-and-watch approach until first quarter earnings are released.
-
Improvement in margins and revenue growth is essential before expecting strong volume expansion or sustained momentum.
Transformers and Rectifiers (India) (CMP: Rs 470.30)
Prashanth: Buy on dip
-
The stock is favourably positioned compared to its industry peers.
-
The company’s Q4 earnings show notable improvement, with positive margin trends adding to the strength.
-
Investors may consider holding the stock and accumulating more on price dips.
Disclaimer: The views and opinions expressed by the investment advisers on NDTV Profit are of their own and not of NDTV Profit. NDTV Profit advises users to consult with their own financial or investment adviser before taking any investment decision.
. Read more on Markets by NDTV Profit.